Estado del programa
ReclutamientoFase
Fase 2Inmunoterapia previa permitida
SíEnsayo dirigido por el CRC
SíDrogas
Chemotherapy, PD-1 antibodyEtiquetas
MSI-H/ MMRd, MSS/ MMRpComentarios
Trial in China, for patients who are having surgery for colorectal cancer liver metastasis.
with/without radiotherapy (SBRT} and immunotherapy
The study will how post-operation chemotherapy (the standard of care) works compared to the combination of radiation, immunotherapy (sintilimab, anti PD-1) and chemotherapy (experimental).
Ubicación | Situación |
---|---|
China | |
Fudan University Shanghai Cancer Center Shanghai, Shanghai 200032 |
Reclutamiento |
Contactos
Criterios de inclusión
Criterios de inclusión:
age ≥ 18 years old, female and male
pathological and imaging confirmed colorectal colorectal liver metastases (synchronous or heterochronous)
Metastatic liver lesions <= 5
Primary colorectal cancer under control
Absence of evidence of extra-hepatic diseases
Metastatic liver lesions received resection with insufficient margin (= 70
Adequate organ function without contraindications to surgery, radiotherapy and immunotherapy
Without previous antitumoral immunotherapy
With good compliance
Signed the inform consent
Criterios de exclusión
Criterios de exclusión:
Pregnancy or breast-feeding women
History of other malignancies within 5 years (except cured skin cancer and cervical cancer in situ)
History of uncontrolled epilepsy, central nervous system disease, or psychiatric disorders
Clinically serious heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or worse congestive heart failure or severe arrhythmia requiring pharmacologic intervention, or history of myocardial infarction within the last 12 months
Immunodeficiency disease, autoimmune diseases or long-term using of immunosuppressive agents
Severe uncontrolled recurrent infections
Baseline blood and biochemical indicator do not meet the following criteria: neutrophils >=1.5×10^9/L, Hb >=90g/L, PLT >=100×10^9/L, ALT/AST<=2.5 ULN, Cr <= 1ULN
Allergic to any component of the therapy